HPV Phase Opportunity Position Versamune based immunotherapies as adjuncts or combination partners for HPV-related cancers, highlighting ongoing Phase 3 Versamune HPV trials and the potential to broaden treatment access through u niversity hospitals and oncology networks.

Influenza Immunotherapy Expansion Leverage Infectimune-based flu vaccine development to explore partnerships with academic medical centers and contract research organizations for preclinical and translational studies, aiming to diversify the pipeline and attract collaborators in infectious disease and cancer immunology.

Early Stage Financing Emphasize near-term funding readiness to prospective investors and strategic partners, noting recent $11M financing and a clinical-stage trajectory to facilitate co-development or milestone-driven collaborations with biopharma companies seeking immunotherapy assets.

Clinical Trial Partnerships Target oncology networks and contract research organizations for enrollment support and data-sharing collaborations around Versamune-based therapies, leveraging the Phase 3 launch momentum to accelerate trial timelines and expand global access.

Strategic Awareness Offer thought leadership and sponsored trials at major oncology and immunotherapy conferences to raise visibility among potential licensors, co-developers, and regional partners, aligning with a focused outreach plan around Versamune and Infectimune platforms.